CAJ | 학술논문

目的：评价芪苈强心胶囊治疗高龄慢性心力衰竭患者的临床疗效及安全性，为临床合理用药提供依据。方法入选≥80岁老年慢性心力衰竭患者60例，随机分为对照组和治疗组，每组30例。2组均给予利尿剂、琥珀酸美托洛尔缓释片（倍他乐克）或地高辛等常规西药治疗．治疗组另加服芪苈强心胶囊4粒，每天3次。治疗8周后对比观察临床疗效、血清脑钠肽（ BNP）和心脏彩色Doppler超声心动图检测心功能指标（ CI、LVEF、SV、CO），并观察不良反应。结果疗程结束后治疗组临床总有效率为93?．33％（28/30），高于对照组73．34％（22/30），差异有统计学意义（ P ＜0．05）。 BNP水平2组治疗后均较治疗前降低（ P ＜0．05），治疗组较对照组BNP 水平下降更明显（P ＜0．05）。HR、SV、CO、CI、LVEF值2组治疗后较治疗前有所改善（ P﹤0．05），但2组间比较差异无统计学意义（P﹥0．05）。2组均未发生严重不良反应。结论芪苈强心胶囊辅治慢性心力衰竭疗效明确，安全性好，可作为高龄慢性心力衰竭患者的药物治疗选择之一。
목적：평개기력강심효낭치료고령만성심력쇠갈환자적림상료효급안전성，위림상합리용약제공의거。방법입선≥80세노년만성심력쇠갈환자60례，수궤분위대조조화치료조，매조30례。2조균급여이뇨제、호박산미탁락이완석편（배타악극）혹지고신등상규서약치료．치료조령가복기력강심효낭4립，매천3차。치료8주후대비관찰림상료효、혈청뇌납태（ BNP）화심장채색Doppler초성심동도검측심공능지표（ CI、LVEF、SV、CO），병관찰불량반응。결과료정결속후치료조림상총유효솔위93?．33％（28/30），고우대조조73．34％（22/30），차이유통계학의의（ P ＜0．05）。 BNP수평2조치료후균교치료전강저（ P ＜0．05），치료조교대조조BNP 수평하강경명현（P ＜0．05）。HR、SV、CO、CI、LVEF치2조치료후교치료전유소개선（ P﹤0．05），단2조간비교차이무통계학의의（P﹥0．05）。2조균미발생엄중불량반응。결론기력강심효낭보치만성심력쇠갈료효명학，안전성호，가작위고령만성심력쇠갈환자적약물치료선택지일。
Objective To evaluate the clinical efficacy of Qiliqiangxin capsule and safety on very elderly patients with chronic heart failure , and provide the basis for rational drug use .Methods 60 patients who were ≥80 year old with chronic heart failure were enrolled and randomly divided into control group and the treatment group , 30 cases in each group .2 groups were given diuretics , metoprolol succinate extended release tablets ( metoprolol ) or digoxin and other conventional western medicine, treatment group plus Qiliqiangxin capsule, 3 times a day.After 8 weeks of treatment, observed the clinical efficacy of serum brain natriuretic peptide ( BNP) and cardiac color Doppler echocardiography cardiac function index ( CI, LVEF, SV, CO) , and observed adverse reactions .Results In treatment group after treatment , the total effective rate was 93.33%(28/30), higher than control group of 73.34%(22/30), the difference was statistically significant ( P <0.05). BNP levels in the two groups after treatment were reduced than before treatment ( P <0.05), the treatment group compared with the control group, BNP levels decreased more significantly ( P <0.05).After treatment, HR, SV, CO, CI, LVEF val-ues of the two groups were improved than before treatment ( P <0.05), but no difference between the two groups was statisti-cally significant ( P >0.05).Both two groups found no serious adverse events .Conclusion Qiliqiangxin capsule clearly assisted treatment of chronic heart failure efficacy , safety, and can be used in very elderly patients with chronic heart failure .